Tesofensine overview: 
Chemical name: (RS)-1-(2,3-dihydro-1H-inden-5-yloxy)-3-(dimethylamino)propan-2-ol hydrochloride.
Molecular formula: C₁₇H₂₅NO₂·HCl
Molecular weight: 311.84 g/mol (free base); 348.85 g/mol (hydrochloride salt)
Chemical class: Tropane-like bicyclic compound; triple monoamine reuptake inhibitor (SNDRI).
Appearance: White to off-white crystalline powder; soluble in water and ethanol.
---------
Mechanism of Action:
Tesofensine acts as a potent inhibitor of presynaptic reuptake of the neurotransmitters serotonin (5-HT), noradrenaline (NE), and dopamine (DA), increasing synaptic concentrations of these monoamines.
Central effects: Enhances dopaminergic and noradrenergic signaling in the hypothalamus and reward centers, leading to reduced appetite and increased energy expenditure.
Peripheral effects: Promotes lipid oxidation and may improve insulin sensitivity in preclinical studies.
Pharmacological / Research Insights
Half-life: ~24–48 hours (human data).
Primary research focus: Investigated for obesity, metabolic syndrome, neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s), and mood modulation.
Notable findings (preclinical and early-phase trials): Dose-dependent weight reduction via appetite suppression and enhanced resting energy expenditure.
Improved leptin and insulin sensitivity markers. Potential neuroprotective and cognitive-enhancing effects through dopaminergic and serotonergic balance.
Synergy potential: May complement mitochondrial or neuroendocrine peptides (e.g., Pinealon, Epitalon) in research models exploring energy metabolism, cognition, and aging.
------
Not suitable for combination with any anti-depressant medication.